FIL Limited Form 8.3 - Allergan Plc (3562M)
11 5월 2020 - 3:00PM
UK Regulatory
TIDMTTM TIDM0Y7T
RNS Number : 3562M
FIL Limited
08 May 2020
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing FMR LLC and/or one or more
(Note 1) of its direct or indirect
subsidiaries
And
FIL Limited and/or one
or more of its direct and
indirect subsidiaries
Company dealt in ALLERGAN PLC
==========================
Class of relevant security ORDINARY SHARES
to which the dealings
being disclosed relate
(Note 2)
==========================
Date of dealing 07-May-2020
==========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities 832,710 0.25%
================= ===================
(2) Derivatives (other
than options)
================= ===================
(3) Options and agreements
to purchase/sell
================= ===================
Total 832,710 0.25%
================= ===================
THE ABOVE INCLUDES A TRANSFER OUT OF 67 ORDINARY SHARES.
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/Sale Number of relevant securities Price per unit (Note 5)
Sale 83 195.16 USD/Share
------------------------------ ------------------------
Sale 58 192.82 USD/Share
------------------------------ ------------------------
Purchase 1 194.16 USD/Share
------------------------------ ------------------------
Purchase 427 193.73 USD/Share
------------------------------ ------------------------
Purchase 1 193.89 USD/Share
------------------------------ ------------------------
Sale 1,314 193.69 USD/Share
------------------------------ ------------------------
Sale 1 194.11 USD/Share
------------------------------ ------------------------
Sale 1 194.24 USD/Share
------------------------------ ------------------------
Sale 1 194.31 USD/Share
------------------------------ ------------------------
Sale 1 194.50 USD/Share
------------------------------ ------------------------
Sale 1 194.53 USD/Share
------------------------------ ------------------------
Sale 1 194.62 USD/Share
------------------------------ ------------------------
Sale 1 194.70 USD/Share
------------------------------ ------------------------
Sale 1 194.77 USD/Share
------------------------------ ------------------------
Sale 1 194.79 USD/Share
------------------------------ ------------------------
Sale 1 194.80 USD/Share
------------------------------ ------------------------
Sale 1 194.94 USD/Share
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative
referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 08-May-2020
Contact name Paul Clark
================
Telephone number 00353 1 223 1447
================
If a connected EFM, name
of offeree/offeror with
which connected
================
If a connected EFM, state
nature of connection (Note
10)
================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEXVLFBBELFBBL
(END) Dow Jones Newswires
May 11, 2020 02:00 ET (06:00 GMT)
Allergan (LSE:0Y7T)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Allergan (LSE:0Y7T)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
